CompletedPhase 2

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Canada140 participantsStarted 2016-12-14

Plain-language summary

The standard or usual treatment for this disease may be chemotherapy or other types of treatment to slow the spread of the disease and relieve some symptoms of this cancer.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Salivary carcinoma (excluding adenoid cystic carcinoma histology)
✓. Carcinoma of unknown primary with tumour infiltrating lymphocytes (TILs) and/or expressing PD-L1
✓. Mucosal melanoma
✓. Acral melanoma
✓. Osteosarcoma
✓. Undifferentiated pleomorphic sarcoma
✓. Clear cell carcinoma of the ovary
✓. Squamous cell carcinoma of the anal canal (SCCA)

What they're measuring

Objective Response Rate Measured by RECIST Version 1.1

Timeframe: 48 months

Trial details

NCT IDNCT02879162

SponsorCanadian Cancer Trials Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2021-06-20

Results submitted2024-12-11

View on ClinicalTrials.gov More Advanced Rare Tumours trials